Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Chemoembolization Clear all
Completed Phase 2 Interventional

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

NCT02724540
View directory record Official record
Conditions
Neuroendocrine Tumor, Malignant, Liver Metastases
Interventions
Bland Embolization, Transarterial chemoembolization, Drug Eluting Beads Embolization
Device · Combination Product
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
San Francisco, California • Standford, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Not applicable Interventional

Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients

NCT04933435
View directory record Official record
Conditions
Liver Cancer
Interventions
Quality of life questionnaires
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Not applicable Interventional

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

NCT04883671
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Interventions
Standard of Care, SBRT
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 2 Interventional

Chemo-embolization for Head and Neck Cancer

NCT04595981
View directory record Official record
Conditions
SCCHN, Squamous Cell Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Not yet recruiting Phase 2 Interventional

Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

NCT07682454
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Interventions
Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review
Procedure · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

NCT02821754
View directory record Official record
Conditions
Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions
Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

NCT02764801
View directory record Official record
Conditions
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Lung Chemoemobolization

NCT05672108
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary, Endobronchial Metastases, Colon Cancer, Sarcoma
Interventions
Computed Tomography, Ethiodized Oil, Mitomycin, Transarterial Chemoembolization, Tris-acryl Gelatin Microspheres
Procedure · Drug · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Not listed Phase 2 Interventional

Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer

NCT00006198
View directory record Official record
Conditions
Liver Cancer
Interventions
thalidomide, chemoembolization with doxorubicin/collagen
Drug · Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

NCT00049322
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Transarterial Chemoembolization, Proton Beam Radiotherapy
Procedure · Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

NCT00576056
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib, TACE
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04472767
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Transarterial Chemoembolization
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609
View directory record Official record
Conditions
Clinically Significant Portal Hypertension
Interventions
Placebo, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance

NCT00926536
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
C-arm CT + DSA as needed, DSA only
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

NCT02753881
View directory record Official record
Conditions
Liver Cancer
Interventions
whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional

TATE Versus TACE in Intermediate Stage HCC

NCT03145558
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Tirapazamine, Doxorubicin
Drug
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Irvine, California • Portland, Oregon • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Chemoembolization for Lung Tumors

NCT04200417
View directory record Official record
Conditions
Lung Metastases, Endobronchial Metastases, Pleural Metastases, Mediastinal Metastases
Interventions
Chemoembolization, Mitomycin C, Lipiodol, Embospheres
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

NCT02460991
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
Interventions
DEB-TACE, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated Not applicable Interventional

DEB-TACE for Hepatocellular Carcinoma

NCT02748161
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DEB-TACE
Procedure
Lead sponsor
Surefire Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed

NCT00877071
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
LC Bead loaded with doxorubicin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

NCT00003907
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
cisplatin, doxorubicin, mitomycin, embolization
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
37
States / cities
Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 3 Interventional

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

NCT01318200
View directory record Official record
Conditions
Recurrent Hepatocellular Carcinoma
Interventions
Transarterial Chemoembolization, CyberKnife SBRT
Procedure · Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 19, 2026, 2:26 AM EDT